In future years, allergy company ALK will go all-in on winning the billion-dollar (US) food allergy market, which in spite of a sparse customer base is many times the size of the respiratory allergy market in which ALK has previously placed stakes.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Things are going well for Danish allergy company ALK, which develops and sells immunotherapies for allergies caused by triggers such as house dust mites, pollen and grass.
Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties.